News

Liquidia is seeking to extend the tentative approval of Yutrepia, an inhaled dry powder formulation of treprostinil for pulmonary arterial hypertension (PAH), to include pulmonary hypertension associated with interstitial lung disease (PH-ILD). PH-ILD occurs when blood pressure in the lungs is high due to a disease that causes lung…

Keros Therapeutics has announced that it will launch a Phase 2 trial to assess the effectiveness of KER-012 as an add-on treatment for patients with pulmonary arterial hypertension (PAH). This follows the recent clearance by the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND)…

People with a combination of two lung diseases — specifically pulmonary fibrosis and emphysema, known as CPFE — who also have pulmonary hypertension (PH) were found to be at an increased risk of death in comparison to CPFE patients without PH, according to a new meta-analysis. Having CPFE also…

Tenax Therapeutics has been issued a U.S. patent covering oral levosimendan, also known as TNX-103, for the treatment of pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). The patent (U.S. Patent No. 11,701,355) is expected to provide intellectual property protection for TNX-103 through December 2040.

Babies born preterm, or before 37 weeks of pregnancy, were shown to have a higher risk of developing pulmonary hypertension (PH), primarily between the ages of 1 and 3, according to a study in Sweden. Moreover, that risk was seen to increase as the length of the pregnancy decreased,…

A one-time surgical procedure called pulmonary artery denervation or PADN was linked to a reduced risk of clinical worsening in the long term for people with combined pre- and post-capillary pulmonary hypertension (CpcPH). That’s according to three-year data from a clinical trial involving CpcPH patients who underwent the procedure.

People with precapillary pulmonary hypertension (PH) and a poorly working right ventricle may benefit from ranolazine, which is used for chest pain caused by heart disease. Data from a Phase 4 study where PH patients took ranolazine for about six months showed better right heart function and more sugar…

Exposure to air pollutants significantly increased the risk of pulmonary hypertension (PH), according to a U.K. population study that included almost 500,000 people. Previous or current smoking increased PH risk and mortality even further, suggesting a synergistic relationship, the researchers noted. The large-scale study, “Dynamic association…

Tailored educational videos on healthy eating coupled with online instruction led to helpful dietary changes in a group of pulmonary arterial hypertension (PAH) patients and the likelihood of a better quality of life, a pilot trial in the Netherlands reports. People assigned to one of two diet plans continued…

Zymedi is collaborating with the National Heart, Lung, and Blood Institute (NHLBI) to advance the development of its first-in-class pulmonary arterial hypertension (PAH) treatment candidate ZMA001. The South Korea-based company and the NHLBI, part of the National Institutes of Health, have signed a clinical Cooperative Research and Development…

Note: This story was corrected July 10, 2023, to reflect that attendees at the European Cardiac and Respiratory Societies discussed the therapy Tyvaso with regard to the 2022 pulmonary hypertension diagnosis and treatment guidelines. Pulmonary hypertension (PH) experts are calling for care protocols to expedite patient referrals to…

Algorithm Sciences, which is developing PulmoProst to treat pulmonary arterial hypertension (PAH), has acquired all assets of Flownix Medical, including the Prometra II pump that would deliver the potential therapy. PulmoProst is an infusion formulation of iloprost, a synthetic version of naturally occurring prostacyclin, a substance that…